Outset Medical Reports Improved Q4 & FY25 Financials, Reduced Cash Burn, and Modest 2026 Revenue Guidance
OM sits 46% above its 52-week low of $3.1.
Summary
Outset Medical reported improved Q4 and full-year 2025 financial results, showcasing expanded gross margins and a significant reduction in cash burn, alongside modest revenue growth and 2026 guidance.
Key Events · Earnings and Guidance · OM
-
Q4 & FY2025 Revenue Performance
Full year 2025 revenue increased 5% to $119.5 million, while fourth quarter revenue slightly decreased by 2% to $28.9 million compared to the prior year.
-
Significant Gross Margin Expansion
GAAP gross margin significantly expanded to 42.4% in Q4 2025 (from 36.5% in Q4 2024) and to 39.1% for the full year 2025 (from 33.9% in 2024).
-
Reduced Operating Expenses & Improved Net Loss
Operating expenses declined 8% in Q4 and substantially for the full year 2025, contributing to an improved net loss of $19.5 million in Q4 and $81.7 million for FY2025.
-
Strong Cash Position & Reduced Cash Burn
The company ended 2025 with $173 million in cash and investments, having significantly reduced net cash used in operations to $46 million in 2025 from $116 million in 2024.
Analysis · OM · Industrial Applications And Services
Outset Medical's latest earnings report highlights significant operational improvements, including substantial gross margin expansion and a notable reduction in cash used in operations for 2025. While revenue growth remains modest, the company's strengthened cash position and disciplined expense management are critical for its long-term viability and path to profitability. Investors should monitor continued margin expansion and revenue acceleration in 2026.
At the time of this filing, OM was trading at $4.54 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $82.3M. The 52-week trading range was $3.10 to $21.98. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.